Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents

International Journal of Impotence Research

Volumn 12, Issue , 2000, Pages S25-S31

  Anderson, M S ^a,b   Shankey, T V ^a,b   Lubrano, T ^a   Mulhall, J P ^a,b  

^a Urology Research Laboratory   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cell culture; Fibroblasts; Peyronie s disease

Indexed keywords

COLCHICINE; COLLAGEN; PROSTAGLANDIN E1; STEROID; VERAPAMIL;

ASSAY; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PEYRONIE DISEASE; PLAQUE FORMING CELL; PREPUCE; PRIORITY JOURNAL; TUNICA ALBUGINEA;

ALPROSTADIL; ANTIVIRAL AGENTS; CALCIUM CHANNEL BLOCKERS; CELL SEPARATION; CELLS, CULTURED; COLCHICINE; FIBRINOLYTIC AGENTS; FIBROBLASTS; HUMANS; INTERFERON-ALPHA; MALE; PENILE INDURATION; VERAPAMIL;

EID: 0034521854     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900558     Document Type: Article

References (41)

1. Vorstrnan B, Lockhart J. Peyronie’s disease. Prob Urol 1987; 1: 507-517.
2. Lindsay MB et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950-1984. J Urol 1991; 146: 1007-1009.
3. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991; 12: 17-23.
4. Somers KD et al. Isolation and characterization of collagen in Peyronie’s disease. J Urol 1989: 141: 629-631.
5. Davis CJ. The microscopic pathology of Peyronie’s disease. J Urol 1997; 157: 282-284.
6. Devine CJ, Jordan GH, Somers RD. Peyronie’s disease: cause and surgical treatment. AUA Today 1989; 2: 1.
7. Weidner W, Schroeder-Printzen I, Weiske W, Vosshenrich R. Sexual Dysfunction in Peyronie’s disease: and analysis of 222 patients without previous local plaque therapy. J Urol 1997; 157: 325-328.
8. Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol 1990: 144: 1376-1379.
9. Devine CJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of Peyronie’s lesion. J Urol 1997; 157: 285-290.
10. Somers KD et al. Cell culture of Peyronie’s disease plaque and normal penile tissue. J Urol 1982; 127: 585-588.
11. Gonzalez A et al. Basic fibroblast growth factor in Dupuytren’s contracture. Am J Pathol 1992; 141: 661-671.
12. Alioto RJ, Rosier RN, Burton RI, Puzas JE. Comparative effects of growth factors on fibroblasts of Dupuytren’s tissue and normal palmar fascia. J Hand Surgery 1994; 19A: 442-452.
13. Badalamente MA, Hurst LC, Grandia SK, Sampson SP. Platelet-derived growth factor in Dupuytren’s disease. J Hand Surgery 1992; 17A: 317-333.
14. Lappi et al. Basic FGF in cells derived from Dupuytren’s contracture. J Hand Surgery 1992; 17A: 324-332.
15. Terek RM et al. The expression of platelet-derived growth factor gene in Dupuytren’s contracture. J Bone Joint Surgery 1995; 17A: 1-9.
16. El-Sakka AI et al. An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997; 158: 2284-2290.
17. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. A Rev Biochem 1989; 58: 575-606.
18. El-Sakka AI et al. Peyronie’s disease is associated with an increase in transforming growth factor-beta expression. J Urol 1998;158:1391-1394.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
20. El-Sakka AI et al. The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol 1999; 161: 1980-1983.
21. Taylor EVV. The mechanism of colchicine inhibition of mitosis. I. Kinetics of inhibition and the binding of H3-colchicine. J Cell Biol 1965; 25; 145.
22. Ehrlich HP, Bornstien P. Microtubules in transcellular movement of procollagen. Nature 1972; 238: 257.
23. Taylor AC. Microtubules in the microspikes and cortical neoplasm of isolated cells. J Cell Biol 1966; 28: 155.
24. Dinnarello CA et al. Colchicine therapy for familial Mediterranean fever: a double blind trial. New Engl J Med 1974; 291: 934.
25. Rehman J, Benet A, Melinan A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long term single blind study. Urology 1998; 51: 620-626.
26. Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol 1997; 158: 1395-1399.
27. Lasser A, Vandenberg TL, Vincent MJ, Hellstrom WJ. Intraplaque Verapamil injection for treatment of Peyronie’s disease. J La State Med Soc 1998; 150: 431-434.
28. Wolf JS, Soble JJ, Ratliff TL, Clayman RV. Ureteral cell cultures II; Collagen production and response to pharmacologic agents. J Urol 1996; 156; 2067-2072.
29. Kahari VM et al. TNF-alpha and IFN-gainina suppress the activation of human type I collagen expression by transforming growth factor beta 1. J Clin Invest 1990: 86: 1489-1495.
30. Varga J et al. IFN-gainina reverses the stimulation of collagen but not fibronectin gene expression by TGF-beta. Eur J Clin Invest 1990; 20: 487-492.
31. Duncan MR, Berman B, Nseyo UO. Regulation of proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, beta and gamma. Scand J Urol Nephrol 1991; 25: 89-94.
32. Oreffo RO et al. Effects of interferon alpha on human osteoprogentitor cell growth and differentiation in vitro, J Cell Biochem 1999; 74: 372-385.
33. Torcia M et al. Interferon-alpha-induced inhibition of B16 melanoma cell proliferation: interference with the bFGF autocrine growth circuit. Biochem Biophys Res Commun 1999; 62: 838-844.
34. Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment of Peyronie’s disease with local interferon-alpha 2b. Eur Urol 1995; 28 236-240.
35. Wegner HE, Andresen R, Knipsel IIH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie’s disease. Eur Urol 1997; 32: 190-193.
36. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie’s disease: a pilot study. Br J Urol 1997; 79: 40-42.
37. Lue TF. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie’s disease. J Urol 1998; 159: 1777-1778.
38. Ahuja S et al. A pilot study demonstrating clinical benefit l'roin intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl 1999; 20: 444-448.
39. Moreland RB et al. PGEl suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995; 153: 826-834.
40. Moreland RB, Gupta S, Goldstein I, Traish A. Cyclic AMP modulates TGF-beta-1- induced fibrillar collagen synthesis in cultured human cavernosuin smooth muscle cells. Int J Impot Res 1998; 10: 159-163.
41. Nehra A et al. Transforming growth factor-beta 1 is sufficient to induce fibrosis of rabbit corporus cavernosuin in vivo. J Urol 1999; 162: 910-915.